Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

10.69 -0.21 (-1.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 748,704
Open 10.90
Bid (Size) 10.48 (100)
Ask (Size) 10.75 (1,000)
Prev. Close 10.90
Today's Range 10.65 - 11.24
52wk Range 5.345 - 36.26
Shares Outstanding 54,769,800
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire

Performance

YTD
-57.7%
-57.7%
1 Month
-7.0%
-7.0%
3 Month
-21.9%
-21.9%
6 Month
-55.6%
-55.6%
1 Year
+93.0%
+93.0%

More News

Read More
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Pharmaceuticals (NASDAQ:OLMA) Reports Narrower Q1 Loss, Eyes Fall Breast Cancer Data Readout ↗
Via Chartmill
Olema Pharmaceuticals Inc (NASDAQ:OLMA) Beats Q4 2025 EPS Estimates, Provides Key Pipeline Updates ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Via The Motley Fool
News headline image
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
Via The Motley Fool
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
From DJS Law Group
Via Business Wire
Monday's session: top gainers and losers ↗
Via Chartmill

Frequently Asked Questions

Is Olema Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Olema Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Olema Pharmaceuticals, Inc. - Common Stock trade on?
Olema Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Olema Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Olema Pharmaceuticals, Inc. - Common Stock is OLMA on the Nasdaq Stock Market
What is the current price of Olema Pharmaceuticals, Inc. - Common Stock?
The current price of Olema Pharmaceuticals, Inc. - Common Stock is 10.69
When was Olema Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Olema Pharmaceuticals, Inc. - Common Stock was at 08/21/26 04:00 PM ET
What is the market capitalization of Olema Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Olema Pharmaceuticals, Inc. - Common Stock is 585.49M
How many shares of Olema Pharmaceuticals, Inc. - Common Stock are outstanding?
Olema Pharmaceuticals, Inc. - Common Stock has 585M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.